Monopar Therapeutics, Inc. (MNPR)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$70.65-2.66%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Monopar Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	550,000
EPS	—	-1.094
Annual ending 2026-12-31
Revenue	—	400,000
EPS	—	-2.977
Annual ending 2027-12-31
Revenue	—	27.9M
EPS	—	-2.463

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Reduce net loss per share	A primary condition in Monopar Therapeutics, Inc.'s published investment case. The stated target is EPS loss less negative than -3.14 USD per share.	Improving	EPS loss worsens beyond -3.14 USD per share in FY27	Diluted EPS: $-0.62 per share FY2026-Q2; GAAP. Published target: EPS loss less negative than -3.14 USD per share. Target period ends 2027-12-31; this observation covers 2026-Q2. Source published Aug 12, 2026-0.62 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Extend operational funding through December 31, 2027	Monopar is focused on developing cancer therapies and aims to extend funding through 2027.	Intact	funding not secured through 2027	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Generate meaningful revenue from therapies	A supporting condition in Monopar Therapeutics, Inc.'s published investment case. The stated target is revenue exceeds $15.8 million.	Intact	revenue fails to exceed $15.8 million in FY27	Revenue: $0 FY2026-Q2; GAAP. Published target: revenue exceeds $15.8 million. Target period ends 2027-12-31; this observation covers 2026-Q2. Source published Aug 12, 20260 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: stock_quarterly_financials_fmp. Reference: 2026-Q2. Source status: unverified. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.46

$-3.48 → $-2.46 · observed estimates

FY2027 revenue$0.03B

$0.02B → $0.03B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-3.48	$15,549,419	7 / 7
2026-07-25	$-3.48	$15,549,419	7 / 7
2026-07-26	$-3.48	$15,594,530	7 / 7
2026-07-27	$-3.48	$15,594,530	7 / 7
2026-07-28	$-3.13	$15,840,750	8 / 9
2026-07-29	$-3.48	$15,594,530	7 / 7
2026-07-30	$-3.13	$15,840,750	8 / 9
2026-07-31	$-3.13	$15,840,750	8 / 9
2026-08-01	$-3.48	$15,594,530	7 / 7
2026-08-02	$-3.13	$15,840,750	8 / 9
2026-08-03	$-3.13	$15,840,750	8 / 9
2026-08-04	$-3.13	$15,840,750	8 / 9
2026-08-05	$-3.48	$15,594,530	7 / 7
2026-08-06	$-3.48	$15,594,530	7 / 7
2026-08-07	$-3.48	$15,594,530	7 / 7
2026-08-08	$-3.13	$15,840,750	8 / 9
2026-08-09	$-3.48	$15,594,530	7 / 7
2026-08-10	$-3.48	$15,594,530	7 / 7
2026-08-12	$-3.13	$15,840,750	8 / 9
2026-08-13	$-3.13	$15,840,750	8 / 9
2026-08-14	$-3.48	$15,594,530	7 / 7
2026-08-15	$-3.48	$15,594,530	7 / 7
2026-08-16	$-3.48	$15,594,530	7 / 7
2026-08-17	$-3.48	$15,594,530	7 / 7
2026-08-18	$-3.48	$15,594,530	7 / 7
2026-08-19	$-3.48	$15,594,530	7 / 7
2026-08-20	$-2.51	$27,902,848	7 / 7
2026-08-21	$-2.51	$27,902,848	7 / 7
2026-08-22	$-2.51	$27,902,848	7 / 7
2026-08-23	$-2.51	$27,902,848	7 / 7
2026-08-24	$-2.51	$27,902,848	7 / 7
2026-08-25	$-2.51	$27,902,848	7 / 7
2026-08-26	$-2.51	$27,902,848	7 / 7
2026-08-27	$-2.51	$27,902,848	7 / 7
2026-08-28	$-2.51	$27,902,848	7 / 7
2026-08-29	$-2.51	$27,902,848	7 / 7
2026-08-30	$-2.51	$27,902,848	7 / 7
2026-08-31	$-2.51	$27,902,848	7 / 7
2026-09-01	$-2.51	$27,902,848	7 / 7
2026-09-02	$-2.51	$27,902,848	7 / 7
2026-09-03	$-2.51	$27,902,848	7 / 7
2026-09-04	$-2.51	$27,902,848	7 / 7
2026-09-05	$-2.51	$27,902,848	7 / 7
2026-09-06	$-2.51	$27,902,848	7 / 7
2026-09-07	$-2.51	$27,902,848	7 / 7
2026-09-08	$-2.51	$27,902,848	7 / 7
2026-09-09	$-2.51	$27,902,848	7 / 7
2026-09-10	$-2.51	$27,902,848	7 / 7
2026-09-11	$-2.51	$27,902,848	7 / 7
2026-09-12	$-2.46	$27,902,848	7 / 7
2026-09-13	$-2.46	$27,902,848	7 / 7
2026-09-14	$-2.46	$27,902,848	7 / 7
2026-09-15	$-2.46	$27,902,848	7 / 7
2026-09-16	$-2.46	$27,902,848	7 / 7
2026-09-17	$-2.46	$27,902,848	7 / 7
2026-09-18	$-2.46	$27,902,848	7 / 7
2026-09-19	$-2.46	$27,902,848	7 / 7
2026-09-20	$-2.46	$27,902,848	7 / 7
2026-09-21	$-2.46	$27,902,848	7 / 7
2026-09-22	$-2.46	$27,902,848	7 / 7
2026-09-23	$-2.46	$27,902,848	7 / 7
2026-09-24	$-2.46	$27,902,848	7 / 7
2026-09-25	$-2.46	$27,902,848	7 / 7
2026-09-26	$-2.46	$27,902,848	7 / 7
2026-09-27	$-2.46	$27,902,848	7 / 7
2026-09-28	$-2.46	$27,902,848	7 / 7
2026-09-29	$-2.46	$27,902,848	7 / 7
2026-09-30	$-2.46	$27,902,848	7 / 7
2026-10-01	$-2.46	$27,902,848	7 / 7
2026-10-02	$-2.46	$27,902,848	7 / 7
2026-10-03	$-2.46	$27,902,848	7 / 7
2026-10-04	$-2.46	$27,902,848	7 / 7
2026-10-05	$-2.46	$27,902,848	7 / 7
2026-10-06	$-2.46	$27,902,848	7 / 7
2026-10-07	$-2.46	$27,902,848	7 / 7
2026-10-08	$-2.46	$27,902,848	7 / 7
2026-10-09	$-2.46	$27,902,848	7 / 7
2026-10-10	$-2.46	$27,902,848	7 / 7
2026-10-11	$-2.46	$27,902,848	7 / 7
2026-10-12	$-2.46	$27,902,848	7 / 7
2026-10-13	$-2.46	$27,902,848	7 / 7
2026-10-14	$-2.46	$27,902,848	7 / 7
2026-10-15	$-2.46	$27,902,848	7 / 7
2026-10-16	$-2.46	$27,902,848	7 / 7
2026-10-17	$-2.46	$27,902,848	7 / 7
2026-10-18	$-2.46	$27,902,848	7 / 7
2026-10-19	$-2.46	$27,902,848	7 / 7
2026-10-20	$-2.46	$27,902,848	7 / 7
2026-10-21	$-2.46	$27,902,848	7 / 7
2026-10-22	$-2.46	$27,902,848	7 / 7
2026-10-23	$-2.46	$27,902,848	7 / 7
2026-10-24	$-2.46	$27,902,848	7 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	14	0
2026-06-01	13	0
2026-07-01	13	0
2026-08-01	13	1
2026-09-01	12	1
2026-10-01	11	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 11 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Reduce net loss per shareDiluted EPS: $-0.62 per share
Extend operational funding through December 31, 2027Direct metric needs a verified mapping
Generate meaningful revenue from therapiesRevenue: $0

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-46.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Monopar Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative, clinical-stage biotechnology thesis, with potential progress tied to one key drug program. The multi-year view is on watch: management has made progress on regulatory steps, but the evidence snapshot rates recent performance as weak and overall confidence as low.

What's priced into Monopar Therapeutics, Inc.

The evidence does not provide a valuation comparison or a clear account of what market expectations already assume, so whether MNPR looks cheap or expensive versus peers is unclear. No fragility gates fired, but that does not resolve the uncertainty around expectations.

What the fundamentals likely do

Management says current funds should support operations through at least the end of 2027, and it has initiated a rolling regulatory submission for ALXN1840. Recent results include two reported earnings beats and one miss, while the snapshot still rates financial performance as weak and flags elevated near-term miss risk.

What Monopar Therapeutics, Inc. hinges on

The multi-year thesis hinges on completing the regulatory submission and showing that ALXN1840’s reported clinical benefits support approval and commercialization. Near-term risks include a guidance cut or worsening employment data, while continued strength among healthcare peers could support sector momentum.